{
  "url": "https://www.investing.com/news/analyst-ratings/nrx-pharmaceuticals-stock-price-target-raised-to-34-from-31-at-d-boral-capital-93CH-4206693",
  "authorsByline": "",
  "articleId": "a93282c8fbec4d5db5a2ec1ca315be83",
  "source": {
    "domain": "investing.com",
    "location": {
      "country": "il",
      "county": "Tel Aviv Subdistrict",
      "city": "Tel Aviv-Yafo",
      "coordinates": {
        "lat": 32.0852997,
        "lon": 34.7818064
      }
    }
  },
  "imageUrl": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
  "country": "tr",
  "language": "en",
  "pubDate": "2025-08-22T11:53:35+00:00",
  "addDate": "2025-08-22T12:16:56.664255+00:00",
  "refreshDate": "2025-08-22T12:16:56.664257+00:00",
  "score": 1.0,
  "title": "NRx Pharmaceuticals stock price target raised to $34 from $31 at D. Boral Capital By Investing",
  "description": "NRx Pharmaceuticals stock price target raised to $34 from $31 at D. Boral Capital",
  "content": "Investing.com - D. Boral (OTC: ) Capital raised its price target on NRx Pharmaceuticals, Inc. (NASDAQ: ) to $34.00 from $31.00 on Friday, while maintaining a Buy rating on the stock. According to InvestingPro data, analyst targets for NRXP range from $21.00 to $46.00, with the stock currently trading at $2.53.\n\nThe price target increase reflects an updated model with an elevated probability of success for the company\u2019s ketamine-based therapy, NRX-100, from 70% to 80%.\n\nD. Boral Capital cited the FDA\u2019s expanded Fast Track designation covering all forms of suicidal depression as the key factor behind the adjustment.\n\nThe expanded designation strengthens both the regulatory case and commercial positioning for NRx Pharmaceuticals\u2019 program, according to the research firm.\n\nNRX-100 is NRx Pharmaceuticals\u2019 ketamine-based therapy currently in development for treatment of suicidal depression.\n\nIn other recent news, NRX Pharmaceuticals reported its financial results for the second quarter of 2025, revealing a larger-than-anticipated loss. The company posted earnings per share of -$0.98, which was significantly below the projected -$0.53, marking an EPS surprise of 84.91%. This development was discussed in a recent earnings call, where the company\u2019s financial performance and strategic plans were reviewed. The report highlights the challenges NRX Pharmaceuticals faces in meeting earnings expectations. Investors are likely to scrutinize the company\u2019s future strategies and financial health closely. Further updates on the company\u2019s plans and performance are anticipated in the upcoming quarters.\n\nThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.",
  "medium": "Article",
  "links": [
    "https://www.investing.com/pro/NRXP",
    "https://www.investing.com/equities/boral-adr",
    "https://www.investing.com/equities/big-rock-partners-o"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "NRx Pharmaceuticals stock price target",
      "weight": 0.119212404
    },
    {
      "name": "NRx Pharmaceuticals",
      "weight": 0.10969007
    },
    {
      "name": "NRX Pharmaceuticals",
      "weight": 0.10504342
    },
    {
      "name": "D. Boral Capital",
      "weight": 0.08398877
    },
    {
      "name": "analyst targets",
      "weight": 0.08115145
    },
    {
      "name": "Boral Capital",
      "weight": 0.07782622
    },
    {
      "name": "suicidal depression",
      "weight": 0.07406472
    },
    {
      "name": "financial health",
      "weight": 0.073440924
    },
    {
      "name": "D. Boral",
      "weight": 0.071443535
    },
    {
      "name": "earnings expectations",
      "weight": 0.069810346
    }
  ],
  "topics": [
    {
      "name": "Markets"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.97314453125
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.96240234375
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.95947265625
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.85498046875
    }
  ],
  "sentiment": {
    "positive": 0.66762847,
    "negative": 0.037628256,
    "neutral": 0.2947433
  },
  "summary": "D. Boral Capital has raised its price target on NRx Pharmaceuticals, Inc. (NASDAQ: ) to $34.00 from $31.00, citing the FDA's expanded Fast Track designation covering all forms of suicidal depression as the key factor. The price target increase reflects an updated model with an elevated probability of success for the company's ketamine-based therapy, NRX-100, from 70% to 80%. The company's financial results for the second quarter of 2025 revealed a larger-than-anticipated loss, marking an EPS surprise of 84.91%.",
  "shortSummary": "NRx Pharmaceuticals' stock price was raised to $34.00 from $31.00 due to increased success prospects for its ketamine-based therapy, despite a larger-than-expected loss.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "461a1646a6e4498a818326a6caf6a9a5",
  "places": [],
  "scraped_sources": [],
  "argos_summary": "D. Boral Capital raised its price target for NRx Pharmaceuticals, Inc. to $34.00, maintaining a Buy rating, due to an increased probability of success for its ketamine-based therapy, NRX-100, following the FDA's expanded Fast Track designation for suicidal depression. Despite this positive outlook, NRx Pharmaceuticals reported a larger-than-expected loss in its second quarter of 2025, with an EPS of -$0.98, raising concerns about its financial health and future strategies.",
  "argos_id": "T6V6MG5HB"
}